Introduction
============

Several meta-analyses demonstrated that bone marrow-derived mononuclear cell (BM-MNC) therapy for patients with ischemic heart disease showed slightly but significantly increased left ventricular ejection fraction (LVEF) from 2.51 to 4.77% compared to controls ([@b1-ijsc-11-001]--[@b4-ijsc-11-001]). However, the results of individual patient data including 1,252 patients from 12 randomized clinical trials showed no changes in LVEF (mean difference: 0.96%, 95% confidence interval: −0.2 to 2.1) compared to controls ([@b5-ijsc-11-001]). BM-MNC was not associated with reduced all-cause mortality and morbidity compared to standard therapy for patients with acute myocardial infarction (AMI) ([@b6-ijsc-11-001]). Conversely, BM-MNC reduced mortality, periprocedural adverse events were infrequent, and the incidence of non-fatal myocardial infarction and arrhythmias was reduced in patients with chronic myocardial infarction (CMI) ([@b7-ijsc-11-001]).

Mesenchymal stem cells (MSC) and cardiac stem cells have emerged as breakthrough treatments of myocardial infarction. MSC can be safely obtained from adult bone marrow and enriched and expanded by in vitro culturing. MSC can be safely administered without the need for immunosuppressant agents, and they are less prone to genetic abnormalities and malignant transformation during multiple passages in vitro ([@b8-ijsc-11-001]--[@b10-ijsc-11-001]). Studies in animal models of myocardial infarction have demonstrated the ability of transplanted MSC to engraft and differentiate into cardiomyocytes and vascular cells ([@b11-ijsc-11-001]--[@b13-ijsc-11-001]). MSC have been used in humans for approximately 10 years to repair or regenerate injured heart, either directly or indirectly (through paracrine effects). Clinical trials suggest that intracoronary administration of autologous bone marrow-derived MSC can improve left ventricular function in patients with myocardial infarction ([@b14-ijsc-11-001]). Also, clinical feasibility and safety trials have been published using bone marrow allogeneic mesenchymal cells in patients with myocardial infarction ([@b15-ijsc-11-001], [@b16-ijsc-11-001]).

Mortality is currently regarded as the most important endpoint to evaluate efficacy of heart failure (HF) drugs in regulatory perspectives ([@b17-ijsc-11-001]). Since 2002 ([@b18-ijsc-11-001]), numerous clinical trials on efficacy of stem cell therapy for heart disease have been performed but most of the efficacy have evaluated using surrogate endpoints such as LVEF and infarct size. A previous study reported that improved LVEF (mechanical parameter) and reduced infarct size (regenerative parameter) have correlated with long-term outcomes in heart disease ([@b19-ijsc-11-001]). In addition, the employment of sophisticated imaging like MRI has played a role in accurately detecting regeneration of myocardium in the assessment of stem cell efficacy ([@b20-ijsc-11-001]).

However, no consensus has been developed in MSC treatment of ischemic heart disease focusing on mechanical, regenerative, and clinical outcomes. We conducted a systematic review and meta-analysis based on the current evidence of prospective randomized controlled trials on treatment with MSC in terms of mechanical, regenerative, and clinical outcomes for patients with MI.

Materials and Methods
=====================

Search strategy and study selection
-----------------------------------

This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<http://www.prisma-statement.org/>). A systematic search and critical review of the literature published from inception through December 2017 was performed of the MEDLINE, EMBASE, and Cochrane databases for clinical studies written in English of MSC transplantation in patients with MI using the following terms: "Mesenchymal Stromal Cell", "Mesenchymal Stem cell", "Mesenchymal Progenitor Cell", "Multipotent Mesenchymal Stromal Cells", "Myocardial Infarction" "Cardiovascular Stroke" and "Heart Failure". The complete search strategy was provided in the Supplementary appendix. The inclusion criteria were restricted to the following studies to evaluate the efficacy of MSC treatment: randomized controlled trials (RCT), studies of patients with acute myocardial infarction (AMI) or chronic myocardial infarction (CMI), and studies comparing placebo as a control group. The administration route, origin of MSC, and MSC differentiation were not restricted. Exclusion criteria were in vivo or in vitro studies; injection of cells other than MSC; studies other than RCT, secondary report, poster presentation, review, or editorial; and studies not written in English. Article selection procedures were independently conducted by two authors with standard methods. Two investigators independently screened all titles and abstracts to identify extracted relevant studies that met the inclusion and exclusion criteria and then independently assessed a full text review for relevant studies. Disagreements were resolved by consensus.

Data extraction
---------------

Two investigators extracted data using customized data extraction forms. The following data were extracted: year of publication, country of patient enrollment, numbers of patients allocated to stem cell treatment and control groups, route of stem cell administration, MSC cell type, cell origin, injection dose, follow-up period (months), and whether or not cell differentiation was performed. The efficacy of MSC therapy was assessed in terms of mechanical, regenerative, and clinical outcomes. Mechanical outcomes were evaluated by left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), 6-minute walking distance (6MWD), and wall motion score index (WMSI). Regenerative outcome was assessed by reduced infarct size. Clinical outcomes were evaluated based on all-cause mortality, non-fatal myocardial infarction (MI), arrhythmia, re-hospitalization for HF, and revisualization. Outcome data were extracted up to the maximum follow-up period to evaluate MSC treatment effect. The time point farthest from cell transplantation was used because this was the best predictor of clinical outcome. Mechanical outcome data, including LVEF, LVESV, and LVEDV, were extracted at baseline and at 3, 6, 12, and 24 months to identify changes over time and evaluate length of MSC treatment. Mean changes of LVEF, LVESV, and LVEDV were evaluated at 3, 6, 12, and 24 months from baseline. The trials were assessed for efficacy outcomes at each follow-up point.

For dichotomous outcomes, the number of events was recorded. For continuous outcomes, the mean, standard deviation, and total sample size were recorded for both treatment and control groups. Outcome data were extracted for the maximum follow-up period, and MSC treatment effects were evaluated based on difference between treatment and control groups. If follow-up data were not present in the original article, changes (*Δ*) from baseline to final time point were included in the meta-analysis. All data were extracted in accordance with criteria based on the Cochrane Handbook for Systematic Reviews of Interventions ([@b21-ijsc-11-001]).

Quality assessment
------------------

Two investigators independently assessed the risk of bias for randomized controlled trials using criteria based on the Cochrane Handbook for Systematic Reviews of Interventions ([@b21-ijsc-11-001]). Each study was examined for sequence generation, allocation concealment, masking, performance bias, detection bias, incomplete outcome data, selective outcome reporting, and other bias that might affect the study outcome. Judgments were expressed simply as "low risk of bias," "high risk of bias," or "unclear risk of bias." Overall quality was divided into low risk of bias and high risk of bias. Low risk of bias in overall quality was defined as all of the quality assessment domains evaluated as other than "high risk of bias." Quality assessments were independently conducted by two authors. Disagreements were resolved by discussion between the two authors.

Statistical analyses
--------------------

Outcome data were analyzed using Review Manager 5.3 (Cochrane collaboration). For dichotomous data, MSC treatment effects were calculated as a risk ratio (RR) with 95% confidence intervals (CI) using Mantel-Haenszel methods. For continuous data, MSC treatment effects were presented as weighted mean difference (WMD) if outcomes were measured in the same way across trials. For outcomes measured using different methods, treatment effect data were combined using the standardized mean difference (SMD). Mechanical and regeneration outcome data were pooled using the DerSimonian-Laird random-effects model because of the high degree of heterogeneity. Clinical outcome data were pooled using the fixed effect model because they showed low heterogeneity. The existence of heterogeneity among effect sizes of individual studies was analyzed with the *I*^2^ statistic. Heterogeneity was defined as low (25% to 50%), moderate (50% to 75%), or high (\>75%) ([@b22-ijsc-11-001]).

Because of different disease characteristics with AMI and CMI, MSC treatment effect differed due to the disease itself. Several previous meta-analyses of BM-MNC injection in patients with MI revealed that treatment effect varied depending on route of administration and measurement tools ([@b23-ijsc-11-001]). A previous meta-analysis suggested that randomized controlled trials testing efficacy should be appropriately designed and rigorously applied to avoid bias ([@b4-ijsc-11-001]). Therefore, preplanned subgroup analyses were conducted based on patient characteristics (AMI or CMI), route of delivery (intracoronary, intravenous, or intramyocardial), measurement tools (single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or echocardiography), whether cell differentiation was conducted or not, and overall risk of bias (low risk or high risk) to explore the source of heterogeneity. The likelihood of publication bias was tested graphically and quantitatively using funnel plot and Egger test.

Results
=======

Search results
--------------

The initial search identified 2,272 articles, of which 2,113 references were excluded in the first screening. Of the remaining 159 potentially relevant references, 104 were excluded for being experimental studies, reviews, editorials, or comments. Fifty-five articles were reviews with full text. Fourteen randomized placebo controlled trials of 35 references were eligible for final analysis ([@b14-ijsc-11-001]--[@b16-ijsc-11-001], [@b24-ijsc-11-001]--[@b34-ijsc-11-001]). A summary of the study classification is presented in a PRISMA flow diagram ([Fig. 1](#f1-ijsc-11-001){ref-type="fig"}).

Characteristics of included studies
-----------------------------------

A total of 950 patients (MSC injection group 509, control group 441) from 14 randomized placebo controlled trials were included in the final meta-analysis. Publication years were from 2004 to 2017. Most of the included studies (11 out of 14) were published from 2013 to 2017. Of 12 studies, 6 included acute MI patients ([@b14-ijsc-11-001], [@b15-ijsc-11-001], [@b24-ijsc-11-001], [@b27-ijsc-11-001]--[@b29-ijsc-11-001]), and the other 8 included chronic MI patients ([@b16-ijsc-11-001], [@b25-ijsc-11-001], [@b26-ijsc-11-001], [@b30-ijsc-11-001]--[@b34-ijsc-11-001]). The baseline LVEF of AMI patients ranged from 43.1 to 52.0, and that of CMI patients was between 17.5 and 35.7. MSC was infused into intracoronary (5 studies) ([@b24-ijsc-11-001], [@b27-ijsc-11-001]--[@b30-ijsc-11-001]), intramyocardial (5 studies) ([@b16-ijsc-11-001], [@b25-ijsc-11-001], [@b26-ijsc-11-001], [@b31-ijsc-11-001], [@b32-ijsc-11-001]), and intravenous (2 studies) ([@b14-ijsc-11-001], [@b15-ijsc-11-001]) locations. Total injected cell doses ranged from 1 to 600×10^6^. Follow-up duration was from 3 to 24 months. In 4 of 14 studies, MSC were differentiated into cardiopoietic stem cells or mesenchymal precursor cells ([Table 1](#t1-ijsc-11-001){ref-type="table"}) ([@b16-ijsc-11-001], [@b25-ijsc-11-001], [@b26-ijsc-11-001], [@b34-ijsc-11-001]).

Risk of bias assessment of included studies
-------------------------------------------

A summary of the risk of bias is presented in [Fig. 2](#f2-ijsc-11-001){ref-type="fig"}. Of 14 randomized placebo controlled trials, 12 used computer-generated random sequence numbers to allocate participants. Nine studies mentioned allocation concealment ([@b14-ijsc-11-001]--[@b16-ijsc-11-001], [@b25-ijsc-11-001], [@b26-ijsc-11-001], [@b31-ijsc-11-001]--[@b34-ijsc-11-001]). Eight studies made an effort to maintain double blindness to reduce performance or detection bias ([@b14-ijsc-11-001]--[@b16-ijsc-11-001], [@b26-ijsc-11-001], [@b31-ijsc-11-001]--[@b34-ijsc-11-001]). Eleven studies were evaluated as low risk of bias in terms of incomplete outcome data ([@b14-ijsc-11-001]--[@b16-ijsc-11-001], [@b25-ijsc-11-001], [@b26-ijsc-11-001], [@b28-ijsc-11-001], [@b29-ijsc-11-001], [@b31-ijsc-11-001]--[@b34-ijsc-11-001]). Nine studies were assessed as low risk of bias in selective outcome reporting compared to protocols from the protocol registration site ([@b14-ijsc-11-001]--[@b16-ijsc-11-001], [@b26-ijsc-11-001], [@b28-ijsc-11-001], [@b31-ijsc-11-001]--[@b34-ijsc-11-001]). Eight studies were evaluated as low risk of bias across all quality assessment domains ([@b14-ijsc-11-001]--[@b16-ijsc-11-001], [@b26-ijsc-11-001], [@b31-ijsc-11-001]--[@b34-ijsc-11-001]) that were considered "low risk of bias" in the overall risk of bias assessment ([Table 1](#t1-ijsc-11-001){ref-type="table"}).

Efficacy of MSC
---------------

In terms of mechanical outcomes, all but one study reported the efficacy of MSC using LV function ([@b31-ijsc-11-001]). Mechanical outcomes were evaluated by LVEF, LVESV, LVEDV, and WMSI. WMSI was calculated by dividing the sum of the wall motion score by the number of visualized segments; a normal WMSI was 1. Compared to the control group, LVEF of the MSC treatment group increased by 3.84% (95% CI: 2.32\~5.35, *I*^2^=43), LVESV decreased by 4.65 ml (95% CI: −14.25 to 4.98, *I*^2^=95), LVEDV decreased by 2.06 ml (95% CI: −11.32 to 7.19, *I*^2^=70), and WMSI decreased by 0.05 (95% CI: −0.07 to −0.03) ([Fig. 2](#f2-ijsc-11-001){ref-type="fig"}).

Regenerative outcomes were measured by scar mass. Scar mass was reduced by 1.13 (95% CI: −1.80 to −0.46, *I*^2^=71) at 6 months after MSC treatment. Regarding clinical outcomes, all of the included studies reported all-cause mortality. The mortality rate in the MSC group was lower than that of control group (OR=0.71, 95% CI: 0.35\~1.47, *I*^2^=0%). Incidences of arrhythmia, re-hospitalization for HF, and revascularization in MSC group patients were lower than those of control groups (OR=0.37, 95% CI: 0.14\~1.00, *I*^2^=14%; OR=0.57, 95% CI: 0.32\~1.00, *I*^2^=0%; OR=0.37, 95% CI: 0.17\~2.61, *I*^2^=0%, respectively). However, incidence of non-fatal MI in MSC patients was higher than that of control patients (OR=2.71, 95% CI: 0.32\~22.97, *I*^2^=0%). Though differences in clinical outcomes were not statistically significant, point estimates showed the beneficial effect of MSC on clinical outcome. 6MWD improved by 27.48 m (95% CI: 16.09 to 38.88, *I*^2^=0) compared to the control group. MSC treatment showed benefits on mechanical, regenerative, and clinical outcomes ([Fig. 3](#f3-ijsc-11-001){ref-type="fig"}).

Subgroup analyses
-----------------

Subgroup analysis showed that improvements in LV function were statistically significant in CMI patients. When studies were compared based on the autologous or allergenic origin of MSC, there was greater improvement in autologous origin MSC (4.62, 95% CI: 1.16 to 8.08 vs. 2.78, 95% CI: 0.55 to 5.01, respectively). Regarding route of injection, intracoronary injection was associated with greater reduction in LVEF. Regarding LVEF measurement tools, there was greater improvement in SPECT than MRI or echocardiography. Studies with a high risk of bias showed slightly greater improvement than those with low risk of bias. Heterogeneity disappeared with autologous cell origin, intravenous administration, MRI assessment, and low risk of bias in methodological flaws based on the subgroup analysis ([Table 2](#t2-ijsc-11-001){ref-type="table"}). The likelihood of publication bias was tested using a funnel plot and Egger test for LVEF. The funnel plot was symmetric and the Egger test was not significant (p=0.20), suggesting low susceptibility to publication bias (funnel plot not shown).

Changes in cardiac function times after transfusion of MSC
----------------------------------------------------------

Compared to controls, the MSC treatment group LVEF improved by 5.8%, 7.6%, 2.4%, and 4.4% at 3, 6, 12, and 24 months, respectively, and LVESV decreased by 20.1 ml, 8.7 ml, 7.6 ml, and 8.4 ml, respectively. The MSC treatment group showed greater decreases in LVEDV than the control group at each follow-up point, with decreases of 7.4 ml, 7.4 ml, 6.2 ml, and 12.2 ml, respectively. Trials were assessed for efficacy outcomes at each follow-up point. The results show that LVEF increased after injection of MSC, and this effect was maintained for up to 24 months ([Fig. 4](#f4-ijsc-11-001){ref-type="fig"}).

Discussion
==========

MSC treatment showed benefits on mechanical, regenerative, and clinical outcomes. In terms of mechanical outcomes, the LVEF of the MSC treatment group increased by 3.84% (95% CI: 2.32\~5.35, *I*^2^=43). Cardiac function assessed by LVEF after injection of MSC was evaluated at 3, 6, 12, and 24 months from baseline. The results show that LVEF was increased, an effect that was maintained for up to 24 months. Regenerative outcomes were measured by scar mass and WMSI. Scar mass was reduced by 1.13 (95% CI: −1.80 to −0.46, *I*^2^=71), and WMSI was reduced by 0.05 (95% CI: −0.07 to −0.03) at 6 months after MSC treatment. The mortality rate and incidence of re-hospitalization for HF in MSC patients showed a trend toward reduction compared to the control group, although the differences were not statistically significant because of the low event rate. Six minute walking distance improved by 27.48 m (95% CI: 16.09 to 38.88, *I*^2^=0) in the MSC treatment group compared to the control group. Based on the present evidence, MSC might have a regenerative effect to reduce infarct size and wall motion in the myocardium. Preclinical evidence revealed that differentiation of MSCs to cardiomyocytes does not occur to a significant extent in vivo. Instead, the "paracrine effect" derived from secretion of MSCs is believed to be the dominant mechanism. MSC injection results in secretion of a range of growth factors, cytokines, and chemokines, which could help repair adverse remodeling in persistent ischemia of heart failure ([@b35-ijsc-11-001]).

According to a meta-analysis of BMC treatment effect in ischemic heart failure with similar inclusion criteria as this study, BMC therapy affected mechanical, regenerative, and clinical outcomes. BMC transplantation resulted in improved LVEF (2.92%, 95% CI: 1.91\~3.92), reduced infarct size (−2.25%, 95% CI: −3.55 to −0.95), and significantly lower incidence of all-cause mortality (OR= 0.55, 95% CI: 0.34\~0.89) ([@b36-ijsc-11-001]).

A recent in vivo study compared MSC and BMC cell delivery in a porcine model of chronic ischemic heart disease. This study showed that MSC was more effective than BMC in improving global heart function. Cell therapy was not associated with increased mortality ([@b37-ijsc-11-001]). A preclinical meta-analysis also revealed that MSC were more beneficial in ischemic heart disease than BMC ([@b38-ijsc-11-001]).

The exact mechanisms by which MSC act remain incompletely described. It is likely that there are myriad effects from these versatile stem cells, rather than a single mechanism of action. Research has shown that a number of factors, both in vitro and in vivo, contribute to the salutary effects of MSC therapy after MI. Possible mechanisms include: 1) MSC differentiate into new cardiomyocytes or other cell types ([@b39-ijsc-11-001]), 2) MSC enhance the neovascularization response after myocardial infarction ([@b40-ijsc-11-001]), 3) MSC act as reservoirs for paracrine mediators that are the actual effectors of observed cardiac repair ([@b41-ijsc-11-001]), 4) MSC stimulate endogenous cardiac precursors to repair the damaged tissue ([@b42-ijsc-11-001]). Further research into the precise mechanism might facilitate improved techniques to achieve even more functional repair for damaged hearts, which will benefit patients in the long run.

MI leads to significant cell loss and scar tissue formation. The remaining cardiomyocytes cannot reconstitute necrotic tissue, and cardiac function deteriorates during the ensuing course. The efficacy of MSC therapy in myocardial infarction might contribute to multiple biological mechanisms, including cardiac regeneration, neovascularization, paracrine effect, and immune regulation. MSC isolated from adult bone marrow differentiated into cardiomyocytes in large animal models ([@b43-ijsc-11-001]--[@b45-ijsc-11-001]). Transplantation of MSCs by injection into the myocardium showed positive cardiac markers in infarcted myocardium ([@b43-ijsc-11-001], [@b44-ijsc-11-001]). MSCs can also achieve engraftment and long-term survival in scarred myocardium ([@b35-ijsc-11-001]).

Though MSC have great potential as a new therapy to treat damaged myocardium, it is crucial to address safety concerns in clinical applications. Several reports have raised concerns about tumor formation with the use of BM-derived MSC and malignant tumors when transplanted in vivo ([@b46-ijsc-11-001], [@b47-ijsc-11-001]). Although malignant transformation and tumor formation with MSC are not yet reported in clinical trials, concerns related to the tumorgenicity of MSC were raised by preclinical studies demonstrating increased tumor progression ([@b48-ijsc-11-001]). A clinical study reported that intracoronary infusion of MSC was involved in acute coronary artery occlusion during the BMSC injection procedure ([@b27-ijsc-11-001]).

Conclusions
===========

The findings of this meta-analysis indicate that BM-MSC can be beneficial in improving heart function in the treatment of MI. However, the efficacy of MSC must be further explored through large randomized controlled trials based on rigorous research design. MSC therapy appears to be safe. However, the safety of MSC must be further explored through clinical studies based on a research design that allows systematic monitoring and reporting of safety to establish the appropriate safety profile of MSC. In addition, potential AEs of MSC must be verified by long-term follow-up studies with continuous caution.
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###### 

MSC effect on mechanical outcomes. (A) LVEF (left ventricular ejection fraction); (B) LVESV (left ventricular end-systolic volume); (C) LVEDV (left ventricular end-diastolic volume); (D) WMSI (wall motion score index).
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![MSC effect on regenerative and clinical outcomes. (A) Scar mass; (B) 6MWD (6-minute walking distance); (C) all-cause mortality; (D) re-hospitalization for heart failure (HF).](ijsc-11-001f3){#f3-ijsc-11-001}

![Mean changes of cardiac function with MSC compared to control at baseline and at 3, 6, 12, and 24-month follow-up.\
\*Numbers in the table indicate the numbers of trials including analysis at each follow-up point. LVEF: left ventricle ejection fraction; LVEDV: left ventricle end-diastolic volume; LVESV: left ventricle end-systolic volume. Error bars indicated 95% Confidence Interval.](ijsc-11-001f4){#f4-ijsc-11-001}

###### 

Characteristics of included studies

  Study               Country of Pts' enrollment                                                      Disease   N     Baseline LVEF (Mean)   Route of delivery   MSC origin   Cell origin   Cell dose (×10^6^)   Measurement tool   MSC differentiation                                F/U (mo)   RoB        
  ------------------- ------------------------------------------------------------------------------- --------- ----- ---------------------- ------------------- ------------ ------------- -------------------- ------------------ -------------------------------------------------- ---------- ----- ---- ------
  Ascheim (2014)      USA                                                                             CMI       20    10                     17.5                19.3         IM            BM                   Allo               25                                                 Echo       Yes   3    High
  Bartolucci (2017)   Chile                                                                           CMI       15    15                     32.6                29.6         IV            UC                   Allo               1                                                  MRI        No    12   Low
  Bartunek (2013)     Belgium, Serbia, Switzerland                                                    CMI       32    15                     27.5                27.8         IM            BM                   Auto               2                                                  Echo       Yes   6    Low
  Chen (2004)         China                                                                           AMI       35    34                     49.0                48.0         IC            BM                   Auto               5                                                  SPECT      No    6    High
  Chen (2006)         China                                                                           CMI       22    23                     26.0                23.0         IC            BM                   Auto               3.1                                                SPECT      No    12   High
  Chullikana (2015)   India                                                                           AMI       10    10                     43.1                43.4         IV            BM                   Allo               4                                                  Echo       No    6    Low
  Gao (2013)          China                                                                           AMI       21    22                     50.8                51.4         IC            BM                   Auto               2                                                  Echo       No    6    High
  Gao (2015)          China                                                                           AMI       58    58                     52.0                51.1         IC            WJ                   Auto               6                                                  SPECT      No    18   High
  Hare (2009)         USA                                                                             AMI       39    21                     47.3                45.1         IV            BM                   Allo               1                                                  MRI        No    6    Low
  Heldman (2014)      USA                                                                             CMI       19    11                     35.7                28.1         IM            BM                   Allo               1.5                                                MRI        No    12   Low
  Lee (2014)          Korea                                                                           AMI       33    36                     49.0                52.3         IC            BM                   Auto               72                                                 SPECT      No    6    High
  Mathiasen (2015)    Denmark                                                                         CMI       40    20                     28.2                25.1         IM            BM                   Auto               2\~3[\*](#tfn1-ijsc-11-001){ref-type="table-fn"}   MRI        No    6    Low
  Perin (2015)        USA                                                                             CMI       45    15                     31.3                34.6         IM            BM                   Allo               25\~150                                            Echo       Yes   12   Low
  Teerlink (2017)     Hungary, Poland, Belgium, Israel, Italy, Spain, Switzerland, Bulgaria, Serbia   CMI       120   151                    27.0                28.0         IM            BM                   Auto               600                                                Echo       Yes   12   Low

unit=ml;

unit=mol/L;

Tx: treatment, Co: control, LVEF: left ventricular ejection fraction, AMI: acute myocardial infarction, CMI: chronic myocardial infarction, IC: intracoronary, IV: intravenous, IM: intramyocardial, Echo: echocardiography, SPECT: single-photon emission computed tomography, MRI: magnetic resonance imaging, FU: follow-up, BM: bone marrow, WJ: Wharton's jelly, Auto: autologous, Allo: allogeneic, RoB: risk of bias, Low: low risk of bias, High: high risk of bias.

###### 

Subgroup analysis to explore source of heterogeneity on changes in LVEF

  Subgroup                    No. of trials (No. of pts)   Mean difference (95% CI)   *I*^2^
  --------------------------- ---------------------------- -------------------------- --------
  Patients' characteristics                                                           
   AMI                        6 (524)                      4.73 (−0.16 to 9.62)       90.8
   CMI                        7 (223)                      3.66 (1.85 to 5.46)        74.7
  Cell origin                                                                         
   Autologous                 8 (689)                      4.62 (1.16 to 8.08)        90.1
   Allogeneic                 5 (195)                      2.78 (0.55 to 5.01)        0
  Route of delivery                                                                   
   Intracoronary              5 (327)                      5.30 (0.43 to 10.17)       92.4
   Intravenous                3 (108)                      4.87 (0.43 to 8.33)        0
   Intramyocardial            5 (449)                      2.96 (1.45 to 4.47)        29.7
  Measurement tool                                                                    
   SPECT                      4 (284)                      6.40 (1.16 to 11.64)       92.1
   MRI                        3 (145)                      3.72 (1.87 to 5.56)        0
   Echocardiography           6 (455)                      2.34 (0.41 to 4.26)        20
  Cell differentiation                                                                
   Yes                        4 (394)                      2.48 (−0.58 to 5.55)       48.3
   No                         9 (490)                      4.91 (1.66 to 8.17)        87
  Overall risk of bias                                                                
   Low                        5 (468)                      3.09 (1.43 to 4.76)        0
   High                       8 (411)                      6.93 (5.83 to 8.04)        89.1

AMI: acute myocardial infarction; CMI: chronic myocardial infarction; SPECT: single-photon emission computed tomography; MRI: magnetic resonance imaging.
